NEW YORK, NY, January 27, 2014 – On January 15, 2014, Val Bias, Chief Executive Officer, the National Hemophilia Foundation (NHF) along with Eddie Williams, Corporate Vice President of Biopharmaceuticals, Novo Nordisk and Robert Gut, MD, PhD, Vice President, Clinical Development & Medical Affairs, Biopharmaceuticals Novo Nordisk announced the launch of the newly named NHF/Novo Nordisk HANDI Library. The announcement was made during a special ribbon cutting ceremony at the New York City headquarters of the National Hemophilia Foundation. The HANDI Library, created by NHF in 1991, contains the largest collection of information on hemophilia and bleeding disorders in the world. HANDI is the acronym for the Hemophilia and AIDS/HIV Network for the Dissemination of Information.
Through a generous contribution from Novo Nordisk in 2013, making the global healthcare company the exclusive sponsor of the newly named NHF/Novo Nordisk HANDI Library, the National Hemophilia Foundation has undertaken a modernization effort to update and digitize the information in the library. This new digitization effort will allow HANDI’s information specialists to continue to provide the most up-to-date information on hemophilia and bleeding disorders and make its response time to electronic requests more efficient.
“HANDI has now reached a point in its evolution where technological improvements play a crucial role in its future. With the capabilities of the internet and social networking, it is imperative for NHF to convert the written materials in the newly named NHF/Novo Nordisk HANDI Library into electronic format to facilitate increased access to patients with bleeding disorders here in the U.S. and throughout the world”, stated Val Bias, Chief Executive Officer, the National Hemophilia Foundation.
Mr. Bias goes on to say: “Digitizing the library will ensure the stability and safety of all of the documents that have been collected through HANDI since 1991 and increase response time to incoming requests. This project is yet another example of Novo Nordisk’s commitment and support not only to NHF’s mission, but to improving the lives of individuals with bleeding disorders.”
"At Novo Nordisk, our medical mission is the clinical development of novel treatment options and the exchange of medical knowledge in order to improve patient care," adds Robert Gut, MD, PhD, Vice President, Clinical Development & Medical Affairs, Biopharmaceuticals, Novo Nordisk. "Through the partnership with NHF, we are achieving our common goal. Digitalization of the NHF/Novo Nordisk HANDI Library will provide the bleeding disorders community with broader access to trusted information and will significantly reduce response time to inquiries."
Since 1991, HANDI has been NHF’s full-fledged resource center on hemophilia and other bleeding disorders. At its core, HANDI’s mission has always been centered on service – answering questions, fulfilling information requests, providing quality educational publications, making referrals to additional sources of assistance and immediately responding to the needs of the bleeding disorders community. The service has been funded through cooperative agreements with the Centers for Disease Control and Prevention.
HANDI processes approximately 4,500 requests for information annually from a variety of patrons – which include consumers, family members, NHF chapter staff, hemophilia treatment center providers, other health care professionals, teachers, students and the general public. The subject areas of these requests reflect a wide range of needs such as self-infusion, physical therapy, treatment complications, rare factor deficiencies, psychosocial issues, blood safety, bleeding issues in women, and financial and insurance reimbursement issues. HANDI information specialists access and utilize the most up-to-date article reprints, textbooks, educational publications, CD-ROMs, and videos to answer both straightforward and complicated requests.
Over the past 20 years, the newly named NHF/Novo Nordisk HANDI Library has amassed a resource collection that now consists of more than 13,000 items. This collection is the premier resource library in the U.S. and around the world for patrons seeking information about the history of hemophilia, or general information about all inherited bleeding disorders. Individuals can contact HANDI Monday – Friday from 9:00am – 5:00pm eastern standard time at 1-800-42-HANDI (1-800-424-2634) or via email at email@example.com.
About the National Hemophilia Foundation
The National (NHF) is dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy and research. Established in 1948, NHF is based in New York City with 51 chapters throughout the United States. NHF’s programs, initiatives and events are made possible through the generosity of individuals, corporations and foundations as well as through a cooperative agreement with the Centers for Disease Control and Prevention (CDC). NHF’s information resource center (HANDI) is available to answer questions, fulfill information requests, provide quality educational publications, and make referrals to additional sources of assistance. HANDI information specialists are available to answer requests from Monday through Friday, 9:00AM to 5:00PM EST, toll-free by dialing 1.800.42.HANDI (1.800.424.2634) or via e-mail at: firstname.lastname@example.org. NHF’s Living Web site provides comprehensive information on bleeding disorders for kids, adolescents, adults, parents and health educators to promote healthy living through all life stages. HemAware, NHF’s award-winning print and online magazine, reports on issues pertinent to the bleeding disorders community. For more information, visit the National Hemophilia Foundation Web site and follow us on Facebook and Twitter.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com.